Compare Petróleo Brasileiro SA (PBR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs GeneDx Holdings Corp — how do they compare? Petróleo Brasileiro SA trades at $20.95 (market cap $128.30B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Petróleo Brasileiro SA is far larger — about 50.1× GeneDx Holdings Corp's market cap, and Petróleo Brasileiro SA pays a 8.07% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| PBR | WGS | |
|---|---|---|
Market Cap | $128.30B | $2.56B |
Sector | Technology | Technology |
52-Week High | $22.03 | $167.51 |
52-Week Low | $11.54 | $34.51 |
Enterprise Value | $188.72B | $2.60B |
Dividend Yield | 8.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBR trades at $20.83, up 3.53% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a low P/E of 5.26, robust net income margin of 24.52%, and record Q2 2026 earnings beating estimates. Recent news highlights regulatory approvals for new drilling in Brazil and exploration in Ghana, signaling growth potential.
Outlook is positive given low valuation, high profitability, and expansion efforts, but risks include geopolitical factors and oil price volatility. Analyst consensus leans bullish with 50% buy ratings, though the stock faces headwinds from softer crude prices and execution risks in new projects.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
